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Abstract
Persistence of giardiasis after some of the recommended drugs is
occurring with increasing frequency. We describe the follow-up of
four members of a family with giardiasis through microscopic
observation, immunochromatography and PCRs of tpi and b-giardin
genes. Three patients did not respond to tinidazole but they were
cured after quinacrine. However, PCRbecame negative at 2 months
after negativization of stools in two patients and after 1 year in one
patient. In all cases Giardia assemblage B was characterized with high
homology between all isolates. Further studies are needed to
determine the value of PCR in the diagnosis of Giardia infections.
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Giardia duodenalis is a common parasitic infection in returning
travellers [1]. Nitroimidazoles appear to be the drug of choice
[2] but, persistence of the infection in humans after treatment
is not uncommon [3]. Resistance of G. duodenalis to nitroim-
idazoles has been demonstrated or induced in vitro, although its
contribution to the persistence of the parasite after treat-
ment remains unclear [2,4,5]. In addition, it is known that
G. duodenalis infection can be caused by mixed genotypes [6]
and as a result antiparasitic treatment could select resistant
strains. Finally, in patients who fail to respond to treatment, a
re-infection should also be considered, particularly in areas of
high endemicity.
In India, Giardia infection with diarrhoea is highly
prevalent, ranging from 0.4% to 70%, and asymptomatic
cyst passage has been found to be as high as 50% in rural
southern areas [7].
We report the case follow-up of a family of four members
including the father (59 years), the mother (57 years), son 1
(16 years) and son 2 (14 years) that presented with giardiasis
after a trip to India in July 2011. All presented watery
diarrhoea, abdominal pain and aerophagia. Stool samples from
each one were collected before and after each treatment.
Samples were analysed by microscopy following standard
formalin–ether concentration, and by rapid immunochroma-
tography (Stick Cryptosporidium/Giardia/Entamoeba histolytica;
Operon, Zaragoza, SA, Spain). DNA from all the samples was
extracted using a DNA stool kit (IBIAN DNA Stool Kit;
IBIAN Technologies, Zaragoza, Spain) and stored at 20°C
until processing. Giardia duodenalis assemblage was determined
by a PCR of the triosephosphate isomerase (tpi) gene [8]. A
fragment-nested PCR was also used to amplify a fragment of
the b-giardin (bg) gene according to Lalle et al. [9]. Addition-
ally, PCR products were puriﬁed with a GFXTM PCR DNA Gel
Band Puriﬁcation Kit (GE Healthcare, Chalfont St Giles, UK)
and then directly sequenced in both directions. The nucleotide
sequences obtained were analysed using the BIOEDIT alignment
program (http://www.mbio.ncsu.edu/bioedit/bioedit) and com-
pared with randomly obtained assemblage B sequences
deposited in GenBank.
The DNA sequences obtained have been deposited in the
Genetic sequence database (GenBank) at the National Center
for Biotechnical Information under accession numbers
JQ782391–JQ782407.
All four patients presented G. duodenalis cysts in the
microscopic examination of stool samples and received a
single dose of 2 g of tinidazole. One of the sons improved
signiﬁcantly—the stool examination and the immunochroma-
tography fecal test were both negative after 1 month. The
others remained symptomatic after treatment and a new
microscopic examination of stools revealed persistence of
G. duodenalis cysts. In all three cases, HIV test was negative and
the presence of IgA deﬁciency was ruled out. The three
relatives with persistence of symptoms received treatment
with quinacrine (100 mg three times a day for 5 days) and
showed progressive improvement of symptoms. The control
stool examinations of the three patients did not show any
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Giardia cyst in any repeatedly control samples but the mother’s
and father’s samples showed Entamoeba histolytica/dispar cysts
and treatment with paromomycin (500 mg three times daily
for 7 days) was prescribed. (Fig. 1 shows the test results and
the treatment given to each member of the family).
A total of 18 samples (four from both children and ﬁve from
the parents) were analysed (see Table 1). Of these, 12 yielded
positive ampliﬁcation for a 140-bp fragment of the tpi gene
corresponding to Assemblage B whereas none were ampliﬁed
for Assemblage A. Samples from three family members gave
positive ampliﬁcation for tpi gene up to 2 months after the
negativization of the stool examination by microscopy but they
were negative 1 year after the therapy in the two samples that
were analysed. All tpi sequences were almost identical, with
similarities ranging between 99.2% and 100%. Only ﬁve
samples gave positive ampliﬁcation for bg gene. With this
PCR, the persistence of Giardia DNA in the last sample from
the father was conﬁrmed and positive ampliﬁcation was also
obtained for the 3-month sample of the asymptomatic son and
for the other son after quinacrine treatment. Analysis of the
sequences showed a range of similarities between 97.8% and
99.1%. Similarity between b-giardin proteins ranged from
96.4% to 100%. Comparing them with the sequences regis-
tered in GenBank, all the b-giardin sequences of this work
showed high identity with that of the isolate BAH8
(AY072727), with only one to three single nucleotide
polymorphisms, indicating that the present isolates are clas-
siﬁed into sub-assemblage BIII.
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FIG. 1. Clinical management of cases with imported giardiasis. Samples numbered as 0, 1, 2, 3, 4 correspond to 0: before treatment, 1, 2, 3 and 4:
month 1, 2, 3 and 12 after treatment); +: Stool examination positive for cyst of Giardia duodenalis; –: Stool examination negative for cysts of
G. duodenalis.
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There are increasing reports of refractory giardiasis after
treatment with nitroimidazoles [10]. This might be a result of
re-infection, immunosuppression or drug resistance [11].
To our knowledge, there are few reported cases of refractory
giardiasis monitored over several months and with PCR.
Genotypic analysis of Giardia was performed using tpi and bg
genes because the combination of the two loci provides a
higher discriminatory power for subgenotyping the parasite
[12]. Twelve samples were ampliﬁed using tpi gene and only
ﬁve with the bg gene.
The high identity between isolates, which is seen in the
study of the two genes (tpi and bg), suggests the presence of
the same isolate in all samples, the small variations observed
over time probably being a result of the high genetic variability
of the parasite. However, the techniques available for geno-
typing Giardia have limitations and this is the closest approx-
imation that can be made. Therefore, new target genes are
needed for genotyping to allow a higher certainty in the
differentiation.
All parasites were characterized as Giardia Assemblage B.
Both Assemblage A and B isolates, have been described as
causing different grades of infection in healthy individuals, and
it has been proposed that a particular genotype of G. duode-
nalis could be associated with refractory giardiasis [10]. It has
also been described at least in one case, that when mixed
assemblage giardiasis becomes refractory, Assemblage B
remains [13]. In the family studied here, although an apparently
identical genotype was successfully treated with tinidazole in
one of the sons, the nitroimidazole therapy was ineffective for
the rest of the family. In this regard, other unknown factors,
including host–parasite interactions [10], patient-intrinsic fac-
tors or the amount of inoculum, are probably relevant [11].
Another interesting issue is the appearance of E. histolytica/
dispar after nitroimidazole and quinacrine therapy in both the
mother and father. Although the possibility of a new acquired
infection after these therapies is plausible, it is more likely that
this infection was acquired in India but remained undetected.
Unfortunately, in our laboratory we cannot differentiate
between E. histolytica and E. dispar and it was decided to treat
E. histolytica in both cases.
Surprisingly, in three family members, PCR remained
positive after an effective treatment, even though immuno-
chromatography and stool examination were negative. It is
possible that damaged and unrecognizable cysts are eliminated
in the faeces for a long time. Indeed, in son 2, the PCR result
persisted for at least for 3 months after tinidazole therapy
despite the son being asymptomatic and his stool examinations
being repeatedly negative.
Conversely, it may be that patients partially respond to the
infection, leading to a situation where patients remainT
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asymptomatic but the parasite persists with a low parasitic
load that is undetectable by the conventional techniques (stool
examination or the immunochromatography–faecal test) but
measurable by the more sensitive PCR. Unfortunately we
could not quantify the amount of parasitic DNA by real-time
PCR to check if low parasitic DNA loads are associated with
negative stool examination or immunochromatography. In our
study, the negativization of the stool samples, collected 2–
3 months after treatment with persistent positive PCR,
reinforces this hypothesis. Moreover, we do not know if had
the quinacrine therapy been provided to the second son,
whether the PCR would had become negative earlier.
Whether an alternative therapeutic option can be offered to
patients like those described here remains unclear and further
research is required to interpret the value of PCR in these
cases.
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